Sign In
Buy APRE
$0.762
-0.0022 (-0.288%)
At Close: Jun 03, 2026
ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI Inhibition ACESOT-1051 Trial Expanded to Includ
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
08:30am, Tuesday, 25'th Mar 2025
ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-1
DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treat
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
08:00am, Wednesday, 05'th Feb 2025
DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatm
Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea's experimental drug, ATRN-119, over a 24-hour daily cycle
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher
10:55am, Wednesday, 13'th Nov 2024
After losing some value lately, a hammer chart pattern has been formed for Aprea Therapeutics (APRE), indicating that the stock has found support. This, combined with an upward trend in earnings estim
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates
10:20am, Thursday, 07'th Nov 2024
Aprea Therapeutics, Inc. (APRE) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.86 per share a year ago.
Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need; active enrollment is ongoing at three sites in the U.S.
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
08:30am, Monday, 14'th Oct 2024
DOYLESTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncolog
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
08:30am, Thursday, 10'th Oct 2024
DOYLESTOWN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncolog
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
08:30am, Wednesday, 09'th Oct 2024
DOYLESTOWN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology
UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
05:15pm, Monday, 09'th Sep 2024
DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
04:05pm, Monday, 09'th Sep 2024
DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
08:30am, Wednesday, 28'th Aug 2024
DOYLESTOWN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology
Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates
10:45am, Monday, 12'th Aug 2024
Aprea Therapeutics, Inc. (APRE) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.87 per share a year ago.
